Aim: To investigate the cost–effectiveness of afatinib and erlotinib as second-line therapy for
advanced squamous cell carcinoma of the lung. Materials & methods: A decision-analytic …

Background and aims Lung cancer has the highest mortality rate of all cancers worldwide.
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an …

Objectives To assess the cost-effectiveness of afatinib compared to erlotinib for the treatment
of squamous NSCLC after first-line platinum based therapy from the French healthcare …

Objective The purpose of this study was to evaluate the cost-effectiveness of the combined
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …

Background Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …

Background The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT1523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Objectives Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …

Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …

Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …